丘脑前核脑深部电刺激联合迷走神经刺激治疗耐药性癫痫
本研究回顾性分析33例曾接受迷走神经刺激(VNS)的耐药性癫痫患者,接受丘脑前核脑深部电刺激(ANT-DBS)后平均随访25.5个月,癫痫发作频率平均下降55%,约67%患者发作减少≥50%,且未发现联合治疗相关并发症,提示ANT-DBS前无需移除VNS装置。
要点
- ANT-DBS对既往或正在接受VNS的耐药性癫痫患者有效,发作频率平均下降55%。
- 约67%患者达到发作减少≥50%,且联合治疗未增加并发症风险。
- ANT-DBS前不必常规移除VNS装置,可考虑同期保留或关闭VNS。
核心结论
- ANT-DBS对既往及正在接受VNS治疗的耐药性癫痫患者仍能提供良好疗效,且移除VNS并非ANT-DBS前的必要步骤。
研究设计与样本
- 回顾性分析33例曾接受VNS并后续行ANT-DBS的耐药性癫痫患者,分为标准ANT-DBS组(9例)、ANT-DBS联合功能性VNS组(12例)及ANT-DBS时VNS脉冲发生器移除或关闭组(12例)。
主要发现
- 平均随访25.5个月,癫痫发作频率平均下降55%。
- 约67%的患者癫痫发作频率减少≥50%。
- 各亚组间癫痫发作减少百分比无显著差异。
- VNS后无显著改善的患者中约50%、VNS后有效的患者中约75%在ANT-DBS术后达到发作减少≥50%。
- 未发生与VNS和ANT-DBS联合治疗相关的并发症。
关键数值与推荐
- 癫痫发作频率平均下降55%(平均随访25.5个月)。
- 约67%患者发作频率减少≥50%。
- 各亚组间发作减少百分比无显著差异。
临床怎么用
- 对于既往或正在接受VNS的耐药性癫痫患者,可考虑ANT-DBS治疗而无需预先移除VNS装置。
- 联合治疗未增加并发症风险,支持在临床中根据患者情况保留或调整VNS。
局限性
- 本研究为回顾性分析,样本量较小(33例),随访时间有限,需进一步前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Food and Drug Administration approved the deep brain stimulation of the anterior nucleus of the thalamus (ANT-DBS) as an adjunctive therapy for drug-resistant epilepsy (DRE) in the United States in 2018. The DBS Therapy for Epilepsy Post-Approval Study is further evaluating the safety and effectiveness of ANT-DBS among different patients' groups. For this study, devices for vagus nerve stimulation (VNS) must be removed prior to enrolment. OBJECTIVE: To investigate the outcomes of concomitant ANT-DBS and VNS treatment for DRE. METHODS: A retrospective analysis was performed for 33 patients who underwent ANT-DBS using previous VNS to define distinct subgroups: standard ANT-DBS (9 subjects), ANT-DBS with functional VNS (12 subjects), and ANT-DBS with the VNS implantable pulse generator explanted or turned off at the time of the DBS (12 subjects). Effectiveness and safety data were analyzed across the whole population and among subgroups. RESULTS: A mean decrease in seizure frequency of 55% was observed after a mean follow-up of 25.5 mo. Approximately 67% of patients experienced ≥50% reduction in seizure frequency. Seizure reduction percentage was not significantly different among groups. Approximately 50% of subjects with no appreciable improvement and 75% of those who showed benefit after VNS (including improvement in seizure frequency, seizure severity, and seizure duration or quality of life) achieved a seizure reduction ≥50% after ANT-DBS surgery. There were no complications related to concomitant VNS and ANT-DBS. CONCLUSION: ANT-DBS for DRE provides excellent results despite previous and ongoing VNS therapy. Removal of VNS does not appear to be necessary before ANT-DBS.
引用
- Parisi V, Lundstrom BN, Kerezoudis P, et al. Anterior Nucleus of the Thalamus Deep Brain Stimulation with Concomitant Vagus Nerve Stimulation for Drug-Resistant Epilepsy. Neurosurgery. 2021. PMID: 34333659. doi:10.1093/neuros/nyab253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。